+ Watch HPTX
on My Watchlist
I happen to know everything there is to know about maple syrup! I love maple syrup. I love maple syrup on pancakes. I love it on pizza. And I take maple syrup and put a little bit in my hair when I've had a rough week. What do you think holds it up, slick?
Ugh! I thought I cancelled this pick! Initially, I thought this one would shoot straight down again, but after considering my own trend analysis of the biotech sector, thought I'd better wait a little while longer. I clearly remember hitting cancel like three times! This better go back down. >:
Hyperion is a strange case. Not because the FDA informed them that they wouldn't have a decision on Ravicti by the January 23 PDUFA date - that's sadly become a common occurrence over the last two years. The odd part is that Hyperion chose to telegraph that Hyperion had been approved by elaborating that the reason for the delay was to iron out labeling and post-marketing requirements. The market therefore reacted as though approval had been announced, sending the stock up 25% since the announcement.I see Ravicti approval as a sell-on-the-news event. There's already a standard treatment of urea cycle disorders called Buphenyl. Ravicti is an upgrade with less frequent dosing and better tolerability, but Buphenyl revenues are only about 15M per year. How much will Hyperion be able to chisel out of insurers for an upgrade? Buphenyl developer Ucyclyd chose not to progress Ravicti to approval themselves, opting instead to sell it to Hyperion for 6M upfront, milestones, and royalties. Not a huge vote of confidence that Ravicti will supplant Buphenyl.The only question now is will the news be what everyone apparently thinks it will be, and has approval been completely priced in. If so, I don't think the current iteration of biopharma traders will stick around to see if Ravicti is really worth a 250M market cap.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions